A Phase 2 interventional study of Dusquetide in Behçet Disease, sponsored by Soligenix. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Soligenix · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Behcet Syndrome with a site in Turkey — 9 open to participants now, 10 under way, 3 of them phase 3. Behcet Syndrome · Turkey.
Among the 30 studies in Behcet Syndrome with a site in Turkey, this one is the 15th largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2024, is one of 5 in phase 2, and was the 24th registered.
136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.
Browse Behcet Syndrome studies →9 of the 30 studies in Behcet Syndrome with a site in Turkey are open now. Recruiting first, the newest first:
ÖZLEM NUR TOK YAMAN · Sites in Turkey
Ages 18+ · Healthy volunteers
Chugai Pharmaceutical · Sites in Turkey, United States, Australia and 17 more countries
Ages 18–85
Ataturk University · Sites in Turkey
Ages 18–70 · Healthy volunteers
Amgen · Sites in Turkey, Greece, Israel and 1 more country
Ages 5–18
Amgen · Sites in Turkey, France, Greece and 5 more countries
Ages 2–17
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 28 Behcet Syndrome studies recruiting now, 7 (25%) set no upper age limit and 15 (54%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 50 across 70 interventional studies indexed under Behcet Syndrome.
Median enrollment 83 across the 16 interventional studies, 60 across the 13 observational. Of the 18 that completed or were terminated, 6 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 30 have an industry lead sponsor. The 10 most frequent:
Soligenix is the lead sponsor of 11 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Soligenix has 1 study filed under Behcet Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Behcet Syndrome with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06925698Phase 3Marmara UniversityImmunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease | 2027-04-01 |
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in Behcet Syndrome with a site in Turkey, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a clinical study to see if dusquetide can treat flares of oral and genital ulcers caused by Behcet's Disease. Study participants will receive an infusion of dusquetide twice a week for 4 weeks (8 treatments total), with weekly follow-up visits for an additional 4 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Having received concomitant immune modulating therapy (except colchicine) within:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is an open-label study and all participants will receive SGX945.
Drug: Dusquetide
1.5 mg/mL dusquetide administered as a 4 minute IV infusion, twice per week for 4 weeks
Also known as: SGX945, SGX942
Number of Oral Ulcers
The number of oral ulcers were counted at baseline and each visit during the treatment period.
Time frame: 4 weeks
Number of Genital Ulcers
The number of genital ulcers will be counted at baseline and each visit during the treatment period.
Time frame: 4 weeks
Change in Pain of Oral Ulcers From Baseline to End of Treatment
The pain of oral ulcers was measured using a 100 mm Visual Analog Scale (VAS) at baseline and each visit during the treatment period. The minimum score is 0 mm (no pain) and the maximum score is 100 mm (maximum pain). The change in pain is the difference between the score at baseline and the score at the end of treatment, where a negative value indicates a reduction in pain.
Time frame: 4 weeks
Change in Pain of Genital Ulcers From Baseline to End of Treatment
The pain of genital ulcers was measured using a 100 mm Visual Analog Scale (VAS) at baseline and each visit during the treatment period. The minimum score is 0 mm (no pain) and the maximum score is 100 mm (maximum pain). The change in pain is the difference between the score at baseline and the score at the end of treatment, where a negative value indicates a reduction in pain.
Time frame: 4 weeks
| Milestone | SGX945 |
|---|---|
| Started | 8 |
| Completed | 8 |
| Not completed | 0 |
The number of oral ulcers were counted at baseline and each visit during the treatment period.
| Oral Ulcers | SGX945 |
|---|---|
| Baseline | 2.9 (2 to 5) |
| End of Treatment | 1.6 (-0.4 to 3.6) |
The pain of oral ulcers was measured using a 100 mm Visual Analog Scale (VAS) at baseline and each visit during the treatment period. The minimum score is 0 mm (no pain) and the maximum score is 100 mm (maximum pain). The change in pain is the difference between the score at baseline and the score at the end of treatment, where a negative value indicates a reduction in pain.
| scores on a scale | SGX945 |
|---|---|
| Change in Pain of Oral Ulcers From Baseline to End of Treatment | -47 (-78.3 to -16.5) |
The pain of genital ulcers was measured using a 100 mm Visual Analog Scale (VAS) at baseline and each visit during the treatment period. The minimum score is 0 mm (no pain) and the maximum score is 100 mm (maximum pain). The change in pain is the difference between the score at baseline and the score at the end of treatment, where a negative value indicates a reduction in pain.
No measurements were reported for this outcome.
The number of genital ulcers will be counted at baseline and each visit during the treatment period.
| Genital Ulcers | SGX945 |
|---|---|
| Baseline | 0 (0 to 0) |
| End of Treatment | 0 (0 to 0) |
Collected over From enrollment until end of follow-up, up to 8 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SGX945 | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Event | SGX945 |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/8 |
| Administration site extravasationGeneral disorders | 1/8 |
| Peripheral swellingGeneral disorders | 1/8 |
| Tinnea infectionInfections and infestations | 1/8 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/8 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/8 |
| Sinus bradycardiaCardiac disorders | 1/8 |
| HeadacheNervous system disorders | 1/8 |
| MaculeSkin and subcutaneous tissue disorders | 1/8 |
| HypertensionVascular disorders | 1/8 |
| Age, Continuous(years) | SGX945 |
|---|---|
| Mean | 43 ± 12.2 |
| Sex: Female, Male(Participants) | SGX945 |
|---|---|
| Female | 6 |
| Male | 2 |
| Race (NIH/OMB)(Participants) | SGX945 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 8 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | SGX945 |
|---|---|
| Caucasian | 8 |
| Region of Enrollment(Participants) | SGX945 |
|---|---|
| Turkey | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2024 to primary completion in May 2025, 6 months.
Results were first posted in Aug 2026, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dusquetide
Soligenix